Introduction
Hypertensive cardiac disease features a hypertrophic left ventricle and fibrotic interstitium, which ultimately leads to heart failure (HF) [
1]. These prior alterations are initially adaptive reactions for sustaining ventricular functionality, but persistent hypertrophy is detrimental [
2]. There is increasing evidence that the progression of cardiac hypertrophy (CH) to dilated cardiomyopathy (DCM) is inevitable and which eventually progresses to HF [
3‐
5]. Therefore, suppressing hypertensive CH may impede progression to HF. Although the clinical management of hypertensive heart disease has been explored in multiple dimensions, there remain few feasible medications for preventing or even reversing CH progression [
6].
Clinical and experimental studies have reported the pivotal effect exerted by the renin–angiotensin–aldosterone system in diverse cardiovascular conditions [
7]. As the primary effector of the renin-angiotensin system, angiotensin II (Ang II) is tightly linked to autophagic incompetence, oxidative stress, and the inflammatory response [
8]. Ang II initiates several signaling axes, such as that of MAPK (mitogen-activated protein kinases), AMP-activated protein kinase (AMPK), and NF-κB, to induce cardiac remodeling [
4,
9]. Furthermore, it has been demonstrated that preventing myocardial hypertrophy and fibrosis is possible by inhibiting the Ang II axis.
In Chinese medicine,
Rheum rhabarbarum is extensively used as an herbal drug [
10]. One chief bioactive component from the rhubarb rhizome is rhein (4,5-dihydroxy-anthraquinone-2-carboxylic acid) [
11,
12], which has diverse pharmacological functions such as inflammation resistance [
13], tumor angiogenesis prevention [
14], and hepatoprotection [
15]. Its treatment potential has been investigated in animal experiments involving various other conditions, including chronic kidney disease [
16], liver cancer [
17], rheumatoid arthritis [
18], and osteoarthritis [
19]. Although the findings are encouraging, its specific mechanisms are not completely understood.
Oxidative stress contributes to CH and HF development [
20]. Published work validated the dose–response repression of superoxide production by rhein [
21]. Nemeikaite-Ceniene et al. demonstrated that rhein was a substrate for a wide variety of one electron-reducing flavoenzymes [
22]. The oxidation resistance of rhein has been noted in the liver [
17] and kidneys [
16], vascular endothelial cells [
23], and pancreatic cancer cells [
24]. These studies imply that rhein can likely be used for protection against CH. Nevertheless, data backing this assumption are scarce. In the present study, we examined the assumption that rhein has a CH preventive role, which we accomplished through Ang II challenge in mice. We validated this by repressing the AMPK–FGF23 signaling pathway, where rhein inhibited Ang II-elicited pathological CH.
Materials and methods
Reagents and antibodies
Rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid) is an anthraquinone compound isolated from rhubarb. Rhein [> 98% high-performance liquid chromatography (HPLC) purity] was purchased from Maclaurin (Shanghai, China). Antibodies against phosphor-AMPKα, AMPKαand GAPDH were purchased from Cell Signaling Technology (Boston, USA). The Anti-atrial natriuretic peptide (ANP), Anti-brain natriuretic peptide (BNP), Anti-FGF23, Anti-BAX and Anti-BCL-2 antibodies were from Abclonal (Wuhan, China).
Animals and animal models
Approval was acquired for all animal experiments from The Quzhou Affiliated Hospital of Wenzhou Medical University. In every experiment, 8–10-week-old male mice weighing 24–28 g were placed in a 23 °C room on a 12-h light–dark cycle. For CH induction, the mice were infused subcutaneously daily for 4 weeks with 1.4 mg/kg Ang II (No. A9525; Sigma-Aldrich, St. Louis, MO, USA) by osmotic pumps (model 2004, ALZET) [
25,
26]. Rhein was dissolved in 40% PEG 400–PBS solution by sonication. Regarding rhein therapy, 50 and 100 mg/kg rhein was injected for 4 weeks on consecutive days. The mice in the normal and Ang II-challenged groups received an equal volume of vehicle. 4 weeks post-Ang II infusion, the measurement of hypertrophy was performed according to previous research [
27,
28]. The mice were killed by cervical dislocation, and the hearts and lungs were harvested and the heart weight normalized to tibia length (HW/TL), heart weight normalized to body weight (HW/BW) and lung weight normalized to eight body weight (LW/BW) were evaluated between vehicle- and rhein-treated mice.
Isolation, treatment, and lentivirus transfection of primary cardiomyocytes (CMs) or cardiac fibroblasts (CFs)
Neonatal murine CMs and CFs were isolated from 2–3-day-old C57BL/6 mice. The initial step was cutting the cardiac tissue into approximately 1 mm3 pieces and their subsequent dissociation using collagenase II (0.07%) and trypsin (0.04%). This was followed by dish (100-mm) incubation of resuspended cells to allow 1-h adherence of noncardiac myocytes (primarily CFs) onto the plastic. Next, 5 × 105 CMs were inoculated into each well of 6-well microplates for 48 h at 5% CO2 and 37 °C. After growing the cells in 10% FBS (fetal bovine serum) DMEM (Dulbecco’s modified Eagle’s medium) containing penicillin (100 U/mL)/streptomycin (100 μg/mL) for 48 h, the medium was replaced with serum-free medium for 12-h incubation before experimentation. Then, the cells were treated with low or high concentrations (5 and 25 μM, respectively) of rhein. Normal cells treated with dimethyl sulfoxide (DMSO) were used as the control. The cells were exposed for 24 h to varying concentrations of rhein and Ang II (1 μM) following a 2-h prior application of compound C (10 μM) to the medium.
Immunofluorescence staining
The CM surface area was assessed with immunofluorescence staining with α-actinin (05-384, Merck Millipore). Briefly, CMs grown on coverslips underwent sequential 15-min fixation with 4% paraformaldehyde, 20-min permeabilization in 0.1% Triton X-100, 1-h (at shortest) blocking in 3% BSA (bovine serum albumin), and 2-h incubation with primary antibodies at ambient temperature, followed by washing and 1-h incubation with secondary antibodies under dark and ambient temperature conditions. After every step, the samples were washed three times with PBS. Lastly, the cells were rinsed three times and incubated with DAPI (C1005, Beyotime, Jiangsu, China). The cells were photographed with a confocal microscope (LSM510; Leica, Wetzlar, Germany) while the cell surface area was assessed with ImageJ 1.48v. The excitation wavelength of 405 nm (for exciting DAPI), 488 nm (for exciting the green fluorescein) and 568 nm (for exciting the red fluorescein) were used for imaging.
Primary CFs were fixed in 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 for 5 min to assess their phenotypic transformation. The CFs were blocked with 5% BSA at room temperature for 1 h and incubated with primary antibody against α-SMA at 4 °C overnight. The CFs were rinsed three times with PBS and incubated with the secondary antibody for 1 h at room temperature in the dark. The cells were visualized and photographed under a Nikon fluorescence microscope.
Cell viability assay
CM and CF viability was assessed with Cell Counting Kit-8 (CCK-8, Beyotime). After 48-h culture, the CMs were treated for another 24 h with gradient concentrations (5, 10, 25, 50, 100 μM) of rhein in 96‐well plates. CCK‐8 (10 μL per well) was added to the plates and incubated for 2 h at 37 °C. The absorbance at 450 nm in each well was assessed with a microplate reader (Bio‐Rad).
Wound healing assay and proliferation assay
For the wound healing assay, the CFs were seeded in 6-well plates containing serum-deprived medium for 24 h before wounding. When the CFs were at 90% confluence, a single scratch was made in the monolayer and the medium was replaced with fresh serum-deprived medium. Then, the migration speed was quantified.
CF proliferation was assayed using the CCK-8 assay kit. CFs (3 × 103 cells) were seeded in serum-deprived medium for 24 h. After 24-h and 48-h culture, each well was incubated with CCK-8 solution. The absorbance was read using a spectrophotometer. The experiments involved five replicate wells per group.
Detection of oxidative stress in vivo and in vitro
To detect reactive oxygen species (ROS) levels, the CMs or CFs and heart tissue were incubated for 45 min with dihydroethidium (DHE) dye (Sigma-Aldrich) at 37 °C in a light-protected humidified chamber after Ang II model establishment and rhein treatment. Superoxide anions in the cells were measured in a similar manner using DCFH-DA fluorescent probes (Beyotime). The results were observed with a fluorescence microscope (Carl Zeiss, Jena, Germany), followed by analysis with inverted fluorescent microscopy. Superoxide dismutase (SOD) and glutathione (GSH) activity in the CMs was assayed with the relevant biochemical kits (Beyotime).
Echocardiographic measurements
At 4 weeks following Ang II treatment, the isoflurane (2%)-anaesthetized mice underwent echocardiography with a Vevo 2100 imaging platform (VisualSonics, Toronto, Canada). Parasternal short-axis images were captured at the mid-papillary muscle level to determine the LVEDd and LVESd (left ventricular end-diastolic and end-systolic diameters). The LV ejection fraction (EF%), considered a systolic function indicator, was determined as follows: (LVEDV − LDESV)/LVEDV × 100.
Histological analysis
The mouse heart tissue underwent sequential 24-h paraformaldehyde (4%) fixation, paraffin-embedding, and sectioning into 5-μm pieces. Then, the sections were stained with hematoxylin and eosin (H&E, Servicebio, Wuhan, China) or picrosirius red (PSR) (Servicebio) according to standard procedures for histopathological purposes and analysis of collagen deposition, respectively. The myocyte cross-sectional areas and fibrotic areas were determined with Image-Pro Plus digital image analyzing software (ver. 6.0).
Quantitative real-time PCR (RT-qPCR)
Total RNA was extracted from the CMs, CFs, or cardiac tissue using TRIzol (TaKaRa, Shiga, Japan) as per the manufacturer’s protocol. The total mRNA (1 μg) was reverse-transcribed into complementary DNA using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The qPCR was performed in accordance with standard procedures and the transcript levels were standardized to GAPDH.
Western blotting
Proteins from the cardiac tissue or cultured cells were sampled with radioimmunoprecipitation assay buffer (Beyotime). Equivalent quantities (40–60 μg) of protein were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (7.5–12.5%), and then transferred to polyvinylidene fluoride membranes. The membranes were blocked for 1 h with 5% skimmed milk in TBST at ambient temperature and were incubated overnight with the relevant primary antibodies. Subsequently, the blots were incubated for 1 h with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:1000 dilution) at ambient temperature. The protein levels were quantified with the Quantity One software package (Bio-Rad).
Data and statistical analysis
The results were all presented as the means ± SDs. A normal distribution test was performed to determine whether a parametric or non-parametric test was conducted. Student’s t-test was used for comparisons between two groups. Comparisons of more than 3 groups were carried out by one-way ANOVA. All statistical analyses were performed using GraphPad Prism 8.0 software. Differences were regarded as significant when P < 0.05.
Discussion
The present research explored the role of rhein in Ang II-elicited CH in vitro and myocardial hypertrophy in vivo. Rhein supplementation inhibited Ang II-induced CM hypertrophy, CF phenotypic transformation, and cellular ROS production. In vivo, rhein supplementation significantly suppressed Ang II-induced CH, oxidative stress, and cardiac fibrosis in mice and ameliorated their cardiac functionality. Mechanistic experimentation revealed that rhein suppressed FGF23 expression in Ang II-induced cardiac remodeling in an obvious manner. Furthermore, FGF23 overexpression inhibited the protective effects of rhein in pathological cardiac remodeling. Importantly, rhein could reduce FGF23 expression, mainly through the activation of AMPK. In summary, rhein can serve as a potential therapy of CH via the AMPK–FGF23 axis.
Experimental and clinical works in the last few decades have yielded extensive evidence that ROS can affect many kinds of pivotal cardiac maladaptation traits, such as the hypertrophic reaction, ECM remodeling, and contractile dysfunction [
20,
34]. ROS is derived from many sources in the heart, such as cyclooxygenase, NADPH, lipoxygenase, mitochondria, and xanthine oxidase [
35]. In the course of CH pathology, NADPH cytoplasmic modulatory subunits are transferred to the plasma membrane, thereby stimulating oxidase [
36]. Pathological CH is linked to ROS surplus, which eventually leads to CM apoptosis and heart failure [
26]. Although oxidative stress exerts a pivotal effect on CH occurrence and progression in a wide range of preclinical models, there is no direct targeted therapy for ROS into the clinical field. In our study on the rhein-mediated protective mechanism against pathological CH, we demonstrated the prominent suppressive role of rhein in oxidative stress following hypertrophic stress. Liu et al. demonstrated that rhein increased H9C2 cell viability and weakened the ROS production and apoptosis of cells under hypoxia/reoxygenation injury exposure [
37]. Heo et al. reported that rhein inhibited monocyte migration through decreased ROS generation and initiation of NADPH oxidase p47 (phox) [
38]. In addition, rhein is believed to facilitate diabetic nephropathy involved with ameliorating oxidative stress [
39]. Here, rhein treatment restored antioxidase activity, including that of SOD and GSH, in Ang II-treated CMs and CFs. The elevated NOX2 and NOX4 protein levels after Ang II stimulation in the CMs and CFs were obviously reversed by rhein. Consistent with these findings, rhein significantly suppressed neuronal oxidative stress in Alzheimer disease [
40], hydrogen peroxide-induced oxidative stress in intestinal epithelial cells [
41], and ATP-triggered inflammatory responses in rheumatoid rat fibroblast-like synoviocytes [
18]. Further research is needed to examine whether rhein has similar effects on ROS derived from the mitochondria or other sources.
Released primarily by osteocytes, FGF23 is a hormone that regulates phosphate and vitamin D metabolism [
42]. FGF23 plays a prominent role in regulating CH and HF [
26]. Circulating FGF23 was associated with CH in patients with chronic kidney and heart disease [
43]. In vitro, FGF23 obviously enhanced CM size and hypertrophic gene marker expression [
44]. Recent studies have suggested that FGF23 is closely related to oxidative stress. Excessive FGF23 induced endothelial dysfunction mainly by promoting oxidative stress [
45]. Dong et al. reported that FGF23 induced atrial fibrosis by enhancing ROS levels [
46]. However, the mechanism of FGF23 in cardiac remodeling remains unclear. We found increased FGF23 levels in the CMs, CFs, and heart tissue in response to Ang II stimulation, while the effects were reversed by rhein. Furthermore, FGF23 overexpression weakened the protective effects of rhein in mice following Ang II exposure. We also found that
FGF23 overexpression suppressed the rhein-mediated reduction of ROS generation in CFs and CMs in an obvious manner.
f some activating signaling pathways has been reported, such as that of AMPK–mTOR, MAPK, and NF-κB. In this work, rhein promoted phosphorylated (p)-AMPK levels prominently. Capable of sensing cellular energy and nutrient status, AMPK directly mediates multiple metabolic processes, such as fatty acid oxidation and glycolysis [
47]. AMPK can also mediate other metabolic processes, including that of PI3K, mTOR, and SIRT1 [
48]. AMPK deficiency aggravates Ang II-elicited CH, myocardial infarction, and pressure overload [
49]. Repression of AMPK activity in CH through mTOR signaling has been demonstrated previously [
50]. In murine renal tubular cells, rhein inhibited autophagy by critical molecule regulation in the AMPK-reliant mTOR pathways [
51]. Rhein improved pemetrexed efficacy in managing non–small cell lung cancer by modulating the PI3K–AKT–mTOR pathway [
52]. Many studies have demonstrated the initiation of AMPK by oxidative stress, implying an extra redox-sensing action of AMPK. A769662, the AMPKα2 activator, exerts a cardioprotective role against ROS production and apoptosis [
53]. Ischemia/reperfusion injury can be resisted by metformin-mediated activation through eNOS phosphorylation at Ser1177, and PGC-1α stimulation [
54]. Consistent with the above findings, we proved that rhein suppressed CH by inhibiting AMPK–mTOR signaling. A selective AMPK inhibitor, compound C overturned the declined p-mTOR expression mediated by rhein and the relief of Ang II-elicited CM hypertrophy by rhein. Consistent with this, it impaired the protective effect of rhein on oxidative stress in vitro. Therefore, rhein is a potential medication for targeting AMPK to treat cardiovascular diseases and prevent HF.
Several limitations of our study should be considered to clarify the causative mechanisms of the protective actions of rhein. First, our research was implemented at a mere two doses. The histological concentration, distribution, and pharmacodynamics of rhein are unclear. Further studies are required to identify the optimal dosage and administration method for rhein. Second, other signaling pathways may be associated with CH, such as the PI3K–AKT, TGF-β1–SMAD, and JAK–STAT pathways. Further investigation is required to examine whether rhein can inhibit CH through the abovementioned signaling pathways. Third, previous studies indicated multiple pharmacological functions of rhein, such as inflammatory resistance, anti-apoptotic, and autophagy promotion. Further studies are needed to exclude the probable systemic effects contributing to the hypertrophic resistance.
Conclusively, this work presented the first evidence that rhein prominently attenuated the pathological processes of cardiac remodeling (e.g., oxidative stress, hypertrophy, cardiac dysfunction, fibrosis) after Ang II exposure. Mechanistically, rhein supplementation prevented hypertensive cardiac remodeling by inhibiting AMPK–FGF23 signaling. Therefore, rhein be a potential preventive drug for hypertensive cardiac remodeling.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.